Refractory Chronic Hand Eczema Therapeutics
1. Panretin patent expiration
Treatment: Topical treatment of cutaneous lesions in patients with aids-related kaposi's sarcoma
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5932622 | ADVANZ PHARMA | Method for in vivo modulation of non-malignant skin-related processes with 9-cis-retinoic acid |
Aug, 2016
(9 years ago) | |
Drugs and Companies using ALITRETINOIN ingredient
Market Authorisation Date: 02 February, 1999
Dosage: GEL
More Information on Dosage
PANRETIN family patents
